Jim Green­wood opens new pol­i­cy shop, with an eye on drug price con­trols; Mod­er­na, CRISPR, Mus­tang re­ceive tax breaks in Mass­a­chu­setts

Capi­tol Hill heavy­weight Jim Green­wood is tak­ing his decades of ex­pe­ri­ence in the in­ter­twin­ing worlds of bio­phar­ma and Con­gress to the law firm DLA Piper, where he’s open­ing up a new pol­i­cy and reg­u­la­to­ry prac­tice along­side for­mer Pfiz­er lawyer Ge­of­frey Levitt.

As Con­gress wran­gles over how to bring down drug prices, the for­mer BIO CEO told End­points News in an in­ter­view that his top three pri­or­i­ties will be, “Price con­trols, price con­trols and price con­trols.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER